A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy
| Autor: | Suphat Subongkot, Nuttapong Ngamphaiboon, J. Konmun, Kwanjit Danwilai, A. Sookprasert, B. Sripanidkulchai |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Adult Male Cancer Research medicine.medical_specialty Metoclopramide Organoplatinum Compounds Nausea Vomiting Placebo-controlled study Catechols Placebo Gastroenterology law.invention Ondansetron 03 medical and health sciences Young Adult 0302 clinical medicine Randomized controlled trial Double-Blind Method law Internal medicine Neoplasms Antineoplastic Combined Chemotherapy Protocols medicine Clinical endpoint Humans Anthracyclines Aged Aged 80 and over business.industry Hematology General Medicine Middle Aged 030104 developmental biology Oncology 030220 oncology & carcinogenesis Anesthesia Antiemetics Female medicine.symptom Fatty Alcohols business medicine.drug |
| Zdroj: | Medical oncology (Northwood, London, England). 34(4) |
| ISSN: | 1559-131X |
| Popis: | 6-Gingerol is a natural compound extracted from ginger. Preclinical studies demonstrated that 6-gingerol has an anti-emetic activity by inhibiting neurokinin-1, serotonin, and dopamine receptors. Several clinical trials examined crude ginger powder for preventing chemotherapy-induced nausea and vomiting (CINV), but none of them was conducted with a standardized bioactive compound. Patients who received moderately to highly emetogenic adjuvant chemotherapy were randomized to receive 6-gingerol 10 mg or placebo orally twice daily for 12 weeks. Ondansetron, metoclopramide, and dexamethasone were given to all patients. The primary endpoint was complete response (CR) rate defined as no emesis or rescue treatment at any time. Eighty-eight patients were randomized to receive 6-gingerol (N = 42) or placebo (N = 46). Most patients received highly emetogenic chemotherapy (93%). Overall CR rate was significantly higher in 6-gingerol group as compared with that of the placebo (77 vs. 32%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink